Treatment of resistance to Tivozanib

If a patient develops drug resistance after taking Tivozanib (Tivozanib), he or she should first have a detailed consultation with a doctor to explain the condition and changes in symptoms.医生将评估耐药性的情况，并根据患者的具体情况制定进一步的治疗计划。 Doctors may recommend replacing tivozanib with another targeted therapy that has a different mechanism of action, which could block the growth and survival of drug-resistant cells and provide new treatment opportunities.

Tivozanib is indicated as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) and in adult patients naïve to VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitors who have experienced disease progression after a single course of cytokine therapy for advanced RCC.耐药性往往是多个细胞信号通路或生物过程的累积结果。通过与其他药物的组合使用，可以影响不同的信号通路，从而提高治疗效果并减少耐药性的发展。医生可能会建议与免疫疗法、靶向治疗或化疗等其他药物的联合使用。在某些情况下，患者可能符合参与临床试验的条件。参与临床试验可以提供最新的治疗方法，包括新型药物或治疗策略。医生可以帮助患者找到适合的临床试验项目。

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.